OBJECTIVES: Widespread implementation of health-related quality-of-life (HRQOL) measurement in prostate cancer practice and research requires concise instruments. With 50 questions, the full-length Expanded Prostate Cancer Index Composite (EPIC) is cumbersome to administer outside of studies focusing exclusively on HRQOL. To facilitate HRQOL measurement in a broad range of prostate cancer research and practice settings, we developed and validated an abbreviated version of the EPIC. METHODS: The 50 questions that constitute the full-length EPIC-50 were evaluated to identify the items suitable for elimination while retaining the ability to measure the 5 prostate cancer-specific HRQOL domains of the EPIC-50. The resulting abbreviated version (EPIC-26) was validated using question responses from 252 subjects who had undergone brachytherapy, external beam radiotherapy, or prostatectomy for prostate cancer. The EPIC-26 internal consistency was measured by Cronbach's α coefficient and reliability using test-retest correlation. RESULTS: Using the high item-scale correlations, clinically relevant content, and preservation of domain psychometrics, 26 items were retained in the EPIC-26 from the 50 questions in the full-length EPIC-50. A high correlation was observed between the EPIC-50 and EPIC-26 versions for the urinary incontinence, urinary irritation/obstruction, bowel, sexual, and vitality/hormonal domain scores (all r ≥ 0.96). The correlations between the different domains were low, confirming that EPIC-26 retained the ability to discern the 5 distinct HRQOL domains. The internal consistency and test-retest reliability for EPIC-26 (Cronbach's α ≥ 0.70 and r ≥ 0.69, respectively for all 5 HRQOL domains) supported its validity. CONCLUSIONS: EPIC-26 is a brief, valid, and reliable subjective measure of health quality among patients with prostate cancer and is suitable for measuring the HRQOL among patients undergoing treatment of early-stage prostate cancer.
OBJECTIVES: Widespread implementation of health-related quality-of-life (HRQOL) measurement in prostate cancer practice and research requires concise instruments. With 50 questions, the full-length Expanded Prostate Cancer Index Composite (EPIC) is cumbersome to administer outside of studies focusing exclusively on HRQOL. To facilitate HRQOL measurement in a broad range of prostate cancer research and practice settings, we developed and validated an abbreviated version of the EPIC. METHODS: The 50 questions that constitute the full-length EPIC-50 were evaluated to identify the items suitable for elimination while retaining the ability to measure the 5 prostate cancer-specific HRQOL domains of the EPIC-50. The resulting abbreviated version (EPIC-26) was validated using question responses from 252 subjects who had undergone brachytherapy, external beam radiotherapy, or prostatectomy for prostate cancer. The EPIC-26 internal consistency was measured by Cronbach's α coefficient and reliability using test-retest correlation. RESULTS: Using the high item-scale correlations, clinically relevant content, and preservation of domain psychometrics, 26 items were retained in the EPIC-26 from the 50 questions in the full-length EPIC-50. A high correlation was observed between the EPIC-50 and EPIC-26 versions for the urinary incontinence, urinary irritation/obstruction, bowel, sexual, and vitality/hormonal domain scores (all r ≥ 0.96). The correlations between the different domains were low, confirming that EPIC-26 retained the ability to discern the 5 distinct HRQOL domains. The internal consistency and test-retest reliability for EPIC-26 (Cronbach's α ≥ 0.70 and r ≥ 0.69, respectively for all 5 HRQOL domains) supported its validity. CONCLUSIONS: EPIC-26 is a brief, valid, and reliable subjective measure of health quality among patients with prostate cancer and is suitable for measuring the HRQOL among patients undergoing treatment of early-stage prostate cancer.
Authors: J B Madalinska; M L Essink-Bot; H J de Koning; W J Kirkels; P J van der Maas; F H Schröder Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: A L Potosky; L C Harlan; J L Stanford; F D Gilliland; A S Hamilton; P C Albertsen; J W Eley; J M Liff; D Deapen; R A Stephenson; J Legler; C E Ferrans; J A Talcott; M S Litwin Journal: J Natl Cancer Inst Date: 1999-10-20 Impact factor: 13.506
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Michael Pinkawa; Bernd Gagel; Marc D Piroth; Karin Fischedick; Branka Asadpour; Mareike Kehl; Jens Klotz; Michael J Eble Journal: Eur Urol Date: 2008-03-24 Impact factor: 20.096
Authors: Mehrdad Alemozaffar; Meredith M Regan; Matthew R Cooperberg; John T Wei; Jeff M Michalski; Howard M Sandler; Larry Hembroff; Natalia Sadetsky; Christopher S Saigal; Mark S Litwin; Eric Klein; Adam S Kibel; Daniel A Hamstra; Louis L Pisters; Deborah A Kuban; Irving D Kaplan; David P Wood; Jay Ciezki; Rodney L Dunn; Peter R Carroll; Martin G Sanda Journal: JAMA Date: 2011-09-21 Impact factor: 56.272
Authors: Hiram Alberto Gay; Jeff M Michalski; Daniel A Hamstra; John T Wei; Rodney L Dunn; Eric A Klein; Howard M Sandler; Chris Saigal; Mark Litwin; Deborah Kuban; Larry Hembroff; Peter Chang; Martin G Sanda Journal: Urology Date: 2013-10-16 Impact factor: 2.649
Authors: Desiree Jones; Fengmin Zhao; Michael J Fisch; Lynne I Wagner; Linda J Patrick-Miller; Charles S Cleeland; Tito R Mendoza Journal: Clin Genitourin Cancer Date: 2013-10-12 Impact factor: 2.872
Authors: Ted A Skolarus; Tabitha Metreger; Daniela Wittmann; Soohyun Hwang; Hyungjin Myra Kim; Robert L Grubb; Jeffrey R Gingrich; Hui Zhu; John D Piette; Sarah T Hawley Journal: J Clin Oncol Date: 2019-03-29 Impact factor: 44.544
Authors: Lin Yang; Adam S Kibel; Graham A Colditz; Ratna Pakpahan; Kellie R Imm; Sonya Izadi; Robert L Grubb; Kathleen Y Wolin; Siobhan Sutcliffe Journal: J Urol Date: 2017-07-18 Impact factor: 7.450
Authors: Anne Holck Storås; Martin G Sanda; Montse Ferrer; Jon Håvard Loge; Alv A Dahl; Eivind A S Steinsvik; Ferran Guedea; Milada Cvancarova; Sophie D Fosså Journal: Clin Genitourin Cancer Date: 2014-01-03 Impact factor: 2.872
Authors: Aaron A Laviana; Zhiguo Zhao; Li-Ching Huang; Tatsuki Koyama; Ralph Conwill; Karen Hoffman; Michael Goodman; Ann S Hamilton; Xiao-Cheng Wu; Lisa E Paddock; Antoinette Stroup; Matthew R Cooperberg; Mia Hashibe; Brock B O'Neil; Sherrie H Kaplan; Sheldon Greenfield; David F Penson; Daniel A Barocas Journal: Eur Urol Date: 2020-02-22 Impact factor: 20.096